Press Releases
ARIAD Announces Oral Ridaforolimus Achieved Primary Endpoint of Improved...
ARIAD Pharmaceuticals, Inc. announced top-line data showing that ridaforolimus, an investigational oral mTOR inhibitor, met the primary endpoint of improved progression-free survival (PFS) compared to...
Press Releases
Cook Medical’s Ongoing Drug-Eluting Peripheral Stent Trial Shows Consistent...
An investigational drug-eluting stent (DES) from Cook Medical showed sustained primary patency at two years compared to data collected at one year in the device’s...
Press Releases
Boehringer Ingelheim and Eli Lilly and Company Announce Strategic...
Boehringer Ingelheim and Eli Lilly and Company announced a global agreement to jointly develop and commercialize a portfolio of diabetes compounds currently in mid- and...
Press Releases
Sandoz announces phase II clinical trial for biosimilar version...
Sandoz announced today that it has begun a phase II clinical trial in patients for biosimilar rituximab (Roche's Rituxan® / Mabthera), a leading monoclonal antibody...
Press Releases
Whats on the horizon for pharma sales- a look...
eyeforpharma recently interviewed: Hans Hoogkamer, Business and Science Affairs, Actelion Pharmaceuticals, Daniel Ghozzi, Managing Director CIS, UCB Pharma Russia & Rune Pilegaard Associate Director, Business...
Press Releases
Shire Reports Positive Signal Finding Study of Investigative Use...
Shire plc, the global specialty biopharmaceutical company, today announced results from a study of Vyvanse®, assessing its effect in a model for Excessive Daytime Sleepiness...
Press Releases
Merck Expand Study Investigating Erbitux as 1st Line Treatment...
Merck KGaA announced that recruitment has been completed for the pivotal Phase III EXPAND(a) clinical trial investigating the efficacy of Erbitux® (cetuximab) in treating patients...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.